ARB-1467 Reduces Serum HBsAg in Both HBeAg Negative and HBeAg Positive PatientsResults of Biweekly Dosing from Cohort 4 Expected in 3Q17Additional Study Starting in 2H17 to Evaluate Longer Term Dosing with Immune Modulatory Agents VANCOUVER, British Columbia and WARMINSTER, Pa., April 22, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus …
The post Arbutus Announces ARB-1467 Data Presentation at EASL appeared first on ForexTV.
April 22, 2017 at 01:10PM
from Nasdaq NewsFeed
No comments:
Post a Comment